Targeted Proteomics of Right Heart Adaptation to Pulmonary Arterial Hypertension

Myriam Amsallem; Andrew J. Sweatt; Jennifer Arthur Ataam; Julien Guihaire; Florence Lecerf; Mélanie Lambert; Maria Rosa Ghigna; Md Khadem Ali; Yuqiang Mao; Elie Fadel; Marlene Rabinovitch; Vinicio de Jesus Perez; Edda Spiekerkoetter; Olaf Mercier; Francois Haddad; Roham T. Zamanian

doi:10.1101/2020.06.19.20136028

ABSTRACT

Rationale No prior proteomic screening study has centered on the right ventricle (RV) in pulmonary arterial hypertension (PAH).

Objectives To identify the circulating proteomic profile associated with right heart maladaptive phenotype (RHMP) in PAH.

Methods Plasma proteomic profiling was performed using multiplex immunoassay in 121 PAH patients (discovery cohort from 2008-2011) and 76 (validation cohort from 2012-2014). The association between proteomic markers and RHMP (defined by the Mayo right heart score [combining RV strain, NYHA and NT-proBNP] and Stanford score [RV end-systolic remodeling index, NYHA and NT-proBNP]) was assessed by partial least squares regression. Expression levels of biomarkers were measured in RV samples from PAH patients undergoing transplant and controls, and mice subjected to pulmonary artery banding (PAB).

Measurements and Main Results High levels of hepatic growth factor (HGF), stem cell growth factor beta, nerve growth factor and stromal derived factor-1 were significantly associated with worse Mayo and Stanford scores but not with pulmonary vascular resistance or pressure in both discovery and validation cohorts (this latter had more severe disease features: lower cardiac index and higher NT-proBNP). In both cohorts, HGF added incremental value to the REVEAL score in the prediction of death, transplant, or hospitalization at 3 years. RV expression levels of HGF and its receptor c-Met were higher in end-stage PAH patients than controls, and in PAB mice than shams.

Conclusion High plasma HGF levels are associated with a RHMP and predictive of 3-year clinical worsening. Both HGF and c-Met RV expression levels are increased in PAH.

Scientific Knowledge on the Subject Right heart maladaptation is the main cause of death in patients with pulmonary arterial hypertension (PAH). Recent non-invasive imaging studies have improved right heart adaptive phenotyping in PAH, identifying right ventricular (RV) free-wall longitudinal strain and the RV end-systolic remodeling index as markers of right heart maladaptive phenotypes (RHMP). Emerging evidence suggests a link between inflammation and RV failure in PAH patients and experimental disease models, yet no prior proteomic screening study has centered on the right heart.

What This Study Adds to the Field This targeted proteomics screening study identifies 4 plasma biomarkers of RHMP in two clinical cohorts of patients with PAH. Among them, hepatic growth factor is shown to be prognostic and incremental to the REVEAL risk score for prediction of 3-year death, lung transplant and readmission. HGF and its receptor c-Met are overexpressed in RV tissue samples from PAH patients undergoing transplant as compared to controls, and mice subjected to pulmonary artery banding (PAB), warranting further exploration as a potential right ventricular-specific therapeutic target.

Online data supplements This article has an online data supplement, which is accessible from this issue’s table of content online at www.atsjournals.org.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

None of the authors have any potential conflicts of interest relative to the study. MA has received a 2016 Young Investigator Seed Grant from the Vera Moulton Wall Center at Stanford and a research grant from Actelion Janssen and speaker fees from Bayer. OM has been supported by a public grant overseen by the French National Research Agency as part of the second Investissement d Avenir program (ANR15RHUS0002). ES is funded by Stanford Cardiovascular Institute National Heart Lung Blood Institute (NHLBI) at the National Institute of Health (NIH) R01 HL128734 (ES and MKA) and Department of Defense grant PR161256 (ES and YM). FH has received research grants from Actelion-Janssen and Philips.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Stanford Institutional Review Board approved the study (IRB #14083 and #20942); all subjects provided informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Take-home message: This targeted proteomics study identifies plasma hepatic growth factor (HGF) as associated with a right heart maladaptive phenotype and 3-year outcomes. HGF and its receptor c-Met right ventricular expression are increased in PAH patients and PA banding mice.
Source(s) of funding: None of the authors have any potential conflicts of interest relative to the study. M.A. has received a 2016 Young Investigator Seed Grant from the Vera Moulton Wall Center at Stanford, a research grant from Actelion-Janssen and speaker fees from Bayer. O.M. has been supported by a public grant overseen by the French National Research Agency as part of the second Investissement d’Avenir program (ANR-15-RHUS-0002). E.S. is funded by Stanford Cardiovascular Institute, National Heart Lung Blood Institute (NHLBI) at the National Institute of Health (NIH) R01 HL128734 (E.S. and MK.A.) and Department of Defense grant PR161256 (E.S., Y.M.). F.H. has received research grants from Actelion-Janssen and Philips.